Breaking News

Catalent, Ennaid Therapeutics Ink COVID-19 Program Pact

Catalent will develop a powder-in-capsule formulation of Ennaid’s ENU200 program, a repurposed antiviral drug for the potential treatment of COVID-19

By: Contract Pharma

Contract Pharma Staff

Catalent has entered a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeting COVID-19. Catalent will develop a powder-in-capsule formulation of Ennaid’s ENU200 program, a repurposed oral antiviral drug.   ENU200 was selected by Ennaid as a candidate to treat COVID-19 following a bioinformatic search for in silico identification of prior-approved chemical compounds blocking the coronavirus proteins, spike-S glycoprotein and the key coronavirus enzyme, Mpro. Cata...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters